XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

Thursday, April 27, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

RAANANA, Israel, April 27, 2017 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA)

("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that Mr. Alex Rabinovich has been appointed as a member of the Company's board of directors.

Mr.

Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.

Mr. Josh Levine, XTL's CEO said that: "We are very happy to have Mr. Rabinovich join our Board of Directors and are certain that he can contribute from his vast experience in the capital markets. We would also like to take this opportunity to thank Mr. Bassa for his much appreciated contribution to XTL as a director throughout the years".

XTL has recently reported raising $5.3 million: $2.5 million through a public offering and $2.8 million in a private placement from its existing shareholders, including Mr. Rabinovich and Mr. Bassa.

About XTL Biopharmaceuticals Ltd. (XTL) 

XTL Biopharmaceuticals Ltd., is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases. The Company's lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren's Syndrome (SS). The few treatments currently on the market for these diseases are not effective enough for many patients and some have significant side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.

Cautionary Statement 

This press release may contain forward-looking statements, about XTL's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of XTL's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause XTL's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause XTL's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in XTL's filings with the SEC and in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Form 20-F/A filed with the U.S. Securities and Exchange Commission on April 3, 2017.

For further information, please contact: Investor Relations, XTL Biopharmaceuticals Ltd. Tel: +972-9-955-7080 Email: [email protected] http://www.xtlbio.com

SOURCE XTL Biopharmaceuticals Ltd



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store